Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort

AIDS

Volumn 26, Issue 4, 2012, Pages 465-474

  Van Lelyveld, Steven F L ^a   Gras, Luuk ^b   Kesselring, Anouk ^b   Zhang, Shuangjie ^b   De Wolf, Frank ^b   Wensing, Annemarie M J ^a   Hoepelman, Andy I M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b STICHTING HIV MONITORING   (Netherlands)

Author keywords

AIDS; cardiovascular diseases; CD4 lymphocyte count; HAART; HIV; neoplasms

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANGIOPLASTY; ANUS CANCER; ARTICLE; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONVALESCENCE; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; FEMALE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PHARYNX CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENESCENCE; TREATMENT DURATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84857046136     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834f32f8     Document Type: Article

References (36)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730. (Pubitemid 28534954)
2. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Moller A, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004; 18:89-97. (Pubitemid 38402322)
3. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77. (Pubitemid 47514615)
4. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. ATHENA national observational cohort study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24: 1527-1535.
5. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009; 48:633-639.
6. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52:203-208.
7. Grabar S, Le MV, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
8. Dronda F, Moreno S, Moreno A, Casado JL, Perez-Elias MJ, Antela A. Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4R cell counts after successful virologic suppression. Clin Infect Dis 2002; 35:1005-1009. (Pubitemid 35178319)
9. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the Euro-SIDA study. HIV Med 2003; 4:255-262. (Pubitemid 36949882)
10. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005; 40:288-293. (Pubitemid 41533068)
11. Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:553-558. (Pubitemid 351442024)
12. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. Incomplete peripheral CD4R cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009; 48:787-794.
13. Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, et al. Poor initial CD4R recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008; 48: 541-546.
14. Gras L, van Sighem A, Smit C, Zaheri S, Schuitemaker H, de Wolf F. Monitoring of human immunodeficiency virus (HIV) infection in the Netherlands. Monitoring Report 2009. http://www.hiv-monitoring.nl/nederlands/onderzoek/ monitoringreports/
15. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to (Pubitemid 41022115)
16. Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, et al. CD4R T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis 2008; 47:1093-1101.
17. Nicastri E, Chiesi A, Angeletti C, Sarmati L, Palmisano L, Geraci A, et al. Clinical outcome after 4 years follow-up of HIVseropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol 2005; 76:153-160. (Pubitemid 40593998)
18. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, et al. Effect of baseline-and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426-434. (Pubitemid 44050889)
19. Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006; 20:1727-1736. (Pubitemid 44299364)
20. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group study. J Infect Dis 2006; 194:1098-1107. (Pubitemid 44547649)
21. Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121:998-1008.
22. Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 2008; 14:413-420. (Pubitemid 351499392)
23. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 2011; 117:5582-5590.
24. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-2153.
25. Marin B, Thiebaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-1753.
26. Prosperi MC, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, Giacometti A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 2010; 50:1316-1321.
27. Klein D, Leyden WA, Xu L, Chao CR, Horberg MA, Towner WJ, et al. Contribution of immunodeficiency to coronary heart disease: cohort study of HIV-infected and HIV-uninfected Kaiser Permanente members. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; Boston; 2011. Abstract no. 810.
28. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55:615-619.
29. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, et al. Low CD4R T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435-447.
30. Kesselring AM, Wit F, Smit C, Reiss P, de Wolf F. The role of cART, immunodeficiency and viremia in liver-related events in HIV-1 infected patients. In: Proceedings of the 4th Netherlands Conference on HIV Pathogenesis, Prevention and Treatment; Amsterdam; 2010.
31. Freiberg MS, McGinnis KA, Butt A, Goetz MB, Brown S, Oursler KA, et al. HIV is associated with clinically confirmed myocardial infarction after adjustment for smoking and other risk factors. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; Boston; 2011. Abstract no. 809.
32. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-1067.
33. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543. (Pubitemid 36578959)
34. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIVon survival.NEngl J Med 2009; 360:1815-1826.
35. Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010; 15 (Suppl 1):3-8.
36. Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, et al. Initiation of antiretroviral therapy at higher nadir CD4R T-cell counts is associated with reduced arterial stiffness in HIVinfected individuals. AIDS 2010; 24:1897-1905.